E-LIB Suche - Ergebnisse für: Campone, M.

1

Prognostic value of EndoPredict test in patients with hormo..:

Penault-Llorca, F. ; Dalenc, F. ; Chabaud, S....
ESMO Open. 9 (2024) 5 - p. 103443 , 2024

Link: https://doi.org/10.1016/..

2

258P Real-world (rw) outcomes in patients (pts) with hormon..:

Campone, M. ; Frenel, J-S. ; Kiver, V.I.I....
ESMO Open. 9 (2024) - p. 103279 , 2024

Link: https://doi.org/10.1016/..

3

Abemaciclib plus a nonsteroidal aromatase inhibitor as init..:

Goetz, M.P. ; Toi, M. ; Huober, J....
Annals of Oncology. , 2024

Link: https://doi.org/10.1016/..

4

132P Clinico-pathological characteristics, treatments and s..:

Giugliano, F. ; Bertaut, A. ; Blanc, J....
ESMO Open. 9 (2024) - p. 103119 , 2024

Link: https://doi.org/10.1016/..

5

KS02.5.A OVERALL SURVIVAL ASSOCIATED WITH FIRST-LINE PCV OR..:

Kacimi, S E O ; Dehais, C ; Carpentier, C...
Neuro-Oncology. 25 (2023) Supplement_2 - p. ii4-ii4 , 2023

Link: https://doi.org/10.1093/..

6

P017 Abemaciclib + endocrine therapy (ET) for HR+, HER2-, n..:

Johnston, S. ; Toi, M. ; O'Shaughnessy, J....
The Breast. 68 (2023) - p. S22-S23 , 2023

Link: https://doi.org/10.1016/..

7

257TiP VERITAC-2: A global, randomized phase III study of A..:

Hamilton, E. ; Ma, C.X. ; De Laurentiis, M....
ESMO Open. 8 (2023) 1 - p. 101445 , 2023

Link: https://doi.org/10.1016/..

8

P05.01.B PROGNOSTIC MARKERS OF DNA METHYLATION AND NGS SEQU..:

Kessler, T ; Schrimpf, D ; Doerner, L...
Neuro-Oncology. 25 (2023) Supplement_2 - p. ii43-ii43 , 2023

Link: https://doi.org/10.1093/..

9

SA21 Feasibility Assessment of an Indirect Treatment Compar..:

Shah, A. ; Thaliffdeen, R. ; Proudman, D....
Value in Health. 26 (2023) 12 - p. S545 , 2023

Link: https://doi.org/10.1016/..

10

206P Capivasertib (C) + palbociclib (P) and fulvestrant (F)..:

Neven, P. ; Hamilton, E. ; Pistilli, B....
ESMO Open. 8 (2023) 1 - p. 101395 , 2023

Link: https://doi.org/10.1016/..

11

EE608 Cost Effectiveness Analysis of a Large (Foundation Me..:

Perrier, L ; Tredan, O ; Morelle, M...
Value in Health. 25 (2022) 12 - p. S175 , 2022

Link: https://doi.org/10.1016/..

12

Factors associated with enrolment in clinical trials among ..:

Presti, D. ; Havas, J. ; Soldato, D....
ESMO Open. 7 (2022) 3 - p. 100513 , 2022

Link: https://doi.org/10.1016/..

13

Adjuvant abemaciclib combined with endocrine therapy for hi..:

Rugo, H.S. ; O'Shaughnessy, J. ; Boyle, F....
Annals of Oncology. 33 (2022) 6 - p. 616-627 , 2022

Link: https://doi.org/10.1016/..

14

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone rece..:

André, F. ; Ciruelos, E.M. ; Juric, D....
Annals of Oncology. 32 (2021) 2 - p. 208-217 , 2021

Link: https://doi.org/10.1016/..

15

Final results from the PERUSE study of first-line pertuzuma..:

Miles, D. ; Ciruelos, E. ; Schneeweiss, A....
Annals of Oncology. 32 (2021) 10 - p. 1245-1255 , 2021

Link: https://doi.org/10.1016/..